297 related articles for article (PubMed ID: 1705389)
1. The effects of vitamin K on the generation of des-gamma-carboxy prothrombin (PIVKA-II) in patients with hepatocellular carcinoma.
Sakon M; Monden M; Gotoh M; Kobayashi K; Kanai T; Umeshita K; Endoh W; Mori T
Am J Gastroenterol; 1991 Mar; 86(3):339-45. PubMed ID: 1705389
[TBL] [Abstract][Full Text] [Related]
2. Clinical evaluation of plasma abnormal prothrombin (PIVKA-II) in patients with hepatocellular carcinoma.
Fujiyama S; Morishita T; Sagara K; Sato T; Motohara K; Matsuda I
Hepatogastroenterology; 1986 Oct; 33(5):201-5. PubMed ID: 2433199
[TBL] [Abstract][Full Text] [Related]
3. [Clinical usefulness of plasma PIVKA-II assay and its limitations in patients with hepatocellular carcinoma].
Fujiyama S; Morishita T; Shibata J; Sato T
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1129-38. PubMed ID: 2471453
[TBL] [Abstract][Full Text] [Related]
4. [Evaluation of plasma PIVKA-II as a new marker for hepatocellular carcinoma].
Tada H; Kagawa K; Hikita H; Takeuchi T; Ohta Y; Fukui S; Shintani H; Deguchi T; Okanoue T; Takino T
Gan No Rinsho; 1989 Apr; 35(5):564-70. PubMed ID: 2469809
[TBL] [Abstract][Full Text] [Related]
5. Measurement of immunoreactive prothrombin, des-gamma-carboxy prothrombin, and vitamin K in human liver tissues: overproduction of immunoreactive prothrombin in hepatocellular carcinoma.
Ono M; Ohta H; Ohhira M; Sekiya C; Namiki M
Am J Gastroenterol; 1990 Sep; 85(9):1149-54. PubMed ID: 1697141
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma.
Cui R; Wang B; Ding H; Shen H; Li Y; Chen X
Chin Med J (Engl); 2002 Jan; 115(1):42-5. PubMed ID: 11930656
[TBL] [Abstract][Full Text] [Related]
7. Acarboxy prothrombin (PIVKA II) as a tumour marker for hepatocellular carcinoma and other liver diseases.
Mohamedein A; Yousif-Kadaru AG; Ahmed SA; Saida H; Zaki ZA; Eldin ; Fedail SS
East Afr Med J; 1995 Sep; 72(9):584-7. PubMed ID: 7498046
[TBL] [Abstract][Full Text] [Related]
8. [Studies on the mechanism of elevation of serum PIVKA-II levels in alcoholic liver cirrhosis].
Sakizono K; Oita T; Eto M; Bito S; Takegawa H; Kasakura S
Rinsho Byori; 2002 Mar; 50(3):289-95. PubMed ID: 11985059
[TBL] [Abstract][Full Text] [Related]
9. PIVKA-II during perioperative period in patients with hepato-biliary-pancreatic diseases.
Kanazumi N; Takeda S; Inoue S; Ohshima K; Sugimoto H; Kaneko T; Watanabe K; Nakao A
Hepatogastroenterology; 2000; 47(36):1695-9. PubMed ID: 11149034
[TBL] [Abstract][Full Text] [Related]
10. A study about mechanisms of des-gamma-carboxy prothrombin's production in hepatocellular carcinoma.
Bertino G; Ardiri AM; Boemi PM; Ierna D; Interlandi D; Caruso L; Minona E; Trovato MA; Vicari S; Li Destri G; Puleo S
Panminerva Med; 2008 Sep; 50(3):221-6. PubMed ID: 18927526
[TBL] [Abstract][Full Text] [Related]
11. Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study.
Kim HS; Park JW; Jang JS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Jang MK
J Clin Gastroenterol; 2009; 43(5):482-8. PubMed ID: 19197197
[TBL] [Abstract][Full Text] [Related]
12. Use of serum PIVKA-II (DCP) determination for differentiation between benign and malignant liver diseases.
Lamerz R; Runge M; Stieber P; Meissner E
Anticancer Res; 1999; 19(4A):2489-93. PubMed ID: 10470180
[TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of plasma abnormal prothrombin (des-gamma-carboxy prothrombin) in hepatobiliary malignancies and other diseases.
Nakao A; Suzuki Y; Isshiki K; Kimura Y; Takeda S; Kishimoto W; Nonami T; Harada A; Takagi H
Am J Gastroenterol; 1991 Jan; 86(1):62-6. PubMed ID: 1702578
[TBL] [Abstract][Full Text] [Related]
14. Abnormal prothrombin (PIVKA-II) and hepatocellular carcinoma.
Okuda H; Nakanish T; Furukawa M; Yamagata H; Obata H
Trop Gastroenterol; 1991; 12(2):59-66. PubMed ID: 1719681
[No Abstract] [Full Text] [Related]
15. [Clinical evaluation of PIVKA-II as a marker of hepatocellular carcinoma].
Arima K; Kodama T; Suga M; Sakamoto H; Ohe Y; Yachi A
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 2):3049-52. PubMed ID: 2476968
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical study of protein induced by vitamin K absence or antagonist II in hepatocellular carcinoma.
Ajisaka H; Shimizu K; Miwa K
J Surg Oncol; 2003 Oct; 84(2):89-93. PubMed ID: 14502782
[TBL] [Abstract][Full Text] [Related]
17. [Optimal cut-off value of PIVKA-II for diagnosis of hepatocellular carcinoma--using ROC curve].
Kim MJ; Bae KW; Seo PJ; Jeong IK; Kim JH; Lee BH; Bang KT; Kim DW; Song IH
Korean J Hepatol; 2006 Sep; 12(3):404-11. PubMed ID: 16998292
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group.
Ishii M; Gama H; Chida N; Ueno Y; Shinzawa H; Takagi T; Toyota T; Takahashi T; Kasukawa R
Am J Gastroenterol; 2000 Apr; 95(4):1036-40. PubMed ID: 10763956
[TBL] [Abstract][Full Text] [Related]
19. Plasma abnormal prothrombin levels in patients with small hepatocellular carcinoma.
Tanabe Y; Ohnishi K; Nomura F; Iida S
Am J Gastroenterol; 1988 Dec; 83(12):1386-9. PubMed ID: 2461655
[TBL] [Abstract][Full Text] [Related]
20. Usefulness of simultaneous determination of alpha-fetoprotein and des-gamma-carboxy prothrombin in hepatocellular carcinoma.
Nakao A; Taniguchi K; Inoue S; Harada A; Nonami T; Watanabe K; Takagi H
Semin Surg Oncol; 1996; 12(3):160-3. PubMed ID: 8727604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]